HOME >> BIOLOGY >> NEWS
Macrochem acquires option to license pexiganan

WELLESLEY HILLS, Mass., July 10 /PRNewswire-FirstCall/ -- MacroChem Corporation (OTCBB: MACM - News) today announced that it has signed an exclusive option to acquire exclusive worldwide license rights for drug uses of pexiganan, a novel, small peptide anti-infective for topical treatment of patients with mild diabetic foot infection (DFI), from Genaera Corporation (Genaera).

"We believe this is a unique opportunity for MacroChem to broaden its product portfolio with a product that has already completed two Phase 3 clinical trials. It also fits our strategic focus and complements our lead product candidate, EcoNail(TM) for treatment of nail fungus currently in a fully enrolled Phase 2 trial and progressing on track with an interim assessment of clinical data later this year after all patients have been treated for twenty four weeks," said Robert J. DeLuccia, President and CEO of MacroChem.

Clinical trials with pexiganan previously conducted by Genaera include two Phase 3 trials submitted in a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in 1998. At that time, outstanding issues with CMC (Chemistry, Manufacturing and Controls) and an FDA request for one additional controlled trial precluded approval.

Mr. DeLuccia further noted, "We would be pleased to have pexiganan in our hands since we believe that, if approved, it would be welcomed by physicians and patients for the treatment of diabetic foot infection. In recent years, there have been many advances in the manufacturing of peptides, a better understanding of the treatment of diabetic foot infection, improvements in clinical trial design and execution, and more clarity concerning regulatory requirements for topical anti-infectives with the potential market being even more attractive than before."

He added, "There continues to be a very large and growing incidence of diabetes and, as a result, a growing number of diabetic foot infections in the
'"/>

Contact: Bill Douglass
bdouglass@investorrelationsgroup.com
212-825-3210
MacroChem
10-Jul-2007


Page: 1 2

Related biology news :

1. Biogen Idec acquires Brandeis spin-out
2. Wiley acquires publications from Carpe Diem Communications
3. Ossur hf. acquires the Gibaud Group in France
4. Springer acquires BioTribune Magazine and Biotribune.com
5. Stevens Davidson Laboratory acquires new research vessel
6. Accentia Biopharmaceuticals acquires exclusive license
7. Ossur acquires US orthotics company Royce Medical
8. Molecular Profiling Institute, Inc. acquires NanoBiomics, Inc.
9. European approval of HIV drug darunavir will provide a potent new option with Fuzeon
10. Fat stem cells being studied as option for breast reconstruction
11. Drug offers new options for leukemia patients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/5/2020)... ... February 04, 2020 , ... Crystal ... the company a second patent related to proprietary liquid crystal technology for rapid ... patent from the USPTO issued on December 3, 2019. Together, these patents protect ...
(Date:1/29/2020)... ... 29, 2020 , ... INDIGO Biosciences, Inc. (INDIGO), the recognized ... a record earnings year for 2019. With final numbers to be released to ... increase in revenue and a thirty percent increase in gross profit, and more ...
(Date:1/27/2020)... ... January 27, 2020 , ... Cytonus Therapeutics Inc. today ... tech entrepreneur, and former senior management consultant at McKinsey & Company who holds ... alternative investment firm. , “Chris Thorne has exceptional business acumen with a ...
Breaking Biology News(10 mins):
(Date:1/23/2020)... ... January 22, 2020 , ... Ideal ... cosmetic surgery industry at two recent North American investor forums specializing in medical ... Genuity Medical Technologies & Diagnostics Forum on November 21, 2019 in New York ...
(Date:1/22/2020)... ... January 21, 2020 , ... COBO Technologies ... Genome editing. The partners have agreed to co-develop and market a portfolio of ... and pre-clinical programs. Over the longer-term, the parties aim to develop a COBO ...
(Date:1/10/2020)... (PRWEB) , ... January 09, 2020 , ... ... and expert services, today announced the acquisition of Cunesoft, a move that expands ... the business objectives of life sciences companies. , Based in Munich, Germany, Cunesoft ...
(Date:1/8/2020)... ... January 08, 2020 , ... ... care helps couples and individuals grow their family, has announced that five of ... by Castle Connolly. Since 1991, the renowned publishing company Castle Connolly ...
Breaking Biology Technology:
Cached News: